The Ethical and Scientific Shortcomings of Current Monotherapy Epilepsy Trials in Newly Diagnosed Patients
- 30 June 2001
- journal article
- Published by Elsevier in Epilepsy & Behavior
- Vol. 2 (3) , 193-200
- https://doi.org/10.1006/ebeh.2001.0197
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Early Identification of Refractory EpilepsyNew England Journal of Medicine, 2000
- Safety and efficacy of vigabatrin and carbamazepine in ne wly diagnosed epilepsy: a multicentre randomised double-blind studyThe Lancet, 1999
- OxcarbazepineNeurology, 1999
- A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizuresNeurology, 1998
- Risk of Recurrent Seizures after Two Unprovoked SeizuresNew England Journal of Medicine, 1998
- A Comparison of Continuous Infusion of Alteplase with Double-Bolus Administration for Acute Myocardial InfarctionNew England Journal of Medicine, 1997
- The mortality of epilepsyCurrent Opinion in Neurology, 1996
- Hazards of Inference: The Active Control InvestigationEpilepsia, 1989
- Equipoise and the Ethics of Clinical ResearchNew England Journal of Medicine, 1987
- Comparison of Carbamazepine, Phenobarbital, Phenytoin, and Primidone in Partial and Secondarily Generalized Tonic–Clonic SeizuresNew England Journal of Medicine, 1985